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The immune status of an individual is made up of the
absolute number (cells/μl) and relative ratios of each
category of immune cells. To determine the extent of
similarity of the immune status between individuals
across malignancies, we described the immune status
using quantitative whole blood flow cytometry of ten
immune markers and generated immune phenotypes
from 40 healthy volunteers and 120 patients with glio-
blastoma, renal cell carcinoma, non-Hodgkin’s lymphoma,
ovarian cancer or with a non-malignant condition (acute
lung injury). After normalization, we used unsupervised
hierarchical clustering and principal component analysis
to sort individuals by similarity of immune status into
discreet groups of immune profiles. Immune profiles sort
not only patients by immune similarity, but they also
identify independently regulated immune markers. We
noticed an inverse relationship between the number of
CD14+HLA-DRlo/neg monocytes and CD4+ T cells. We
found that the combination of these markers acted as a
potent novel biomarker for assessing the patients’
immune status. Using survival and immunophenotype
data from glioblastoma, renal cell carcinoma, non-Hodg-
kin’s lymphoma patients, we calculated the ratio of the
number of CD4+ T cells to the number of CD14+HLA-
DRlo/neg monocytes (cells/μl) and subgrouped those
with a high or low ratio, with a cut-point ratio of 2.0.
The 40 healthy volunteers had a mean CD4+/CD14
+HLA-DRlo/neg ratio of 39.8 (median 22.5) with a mini-
mum of 3.9. We analyzed the overall survival of GBM,
NHL, and RCC patients with high and low ratio using
multivariate analysis to control for age and disease type.
The median overall survival for patients with a ratio
above 2.0 was 30 months (n=68) compared to 9 months
for patients with a low ratio (n=39; p=0.006 by multivari-
ate analysis). Thus, the CD4+/CD14+HLA-DRlo/neg
ratio has the potential to be a powerful biomarker for
risk stratification and prognosis for a broad array of
malignancies.
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